Shopping Cart 0
Cart Subtotal
USD 0

AbbVie Inc (ABBV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company that develops, manufactures and commercializes advanced therapies for treating complex and serious diseases. It provides pharmaceutical drugs to treat conditions in rheumatology, gastroenterology, dermatology, oncology, virology and metabolic therapy areas. The company also offers medicines for neurological disorders and other serious health conditions. AbbVie discovers and develops novel medicines based on protein-based and targeted drug delivery technologies. The company its products directly to wholesalers, distributors, health care facilities, government agencies, specialty pharmacies and independent retailers through its own distribution centers and public warehouses across the world. AbbVie is headquartered in North Chicago, Illinois, the US.

AbbVie Inc (ABBV)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 9

List of Figures 11

AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 12

AbbVie Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 13

AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 14

AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 15

AbbVie Inc, Medical Devices Deals, 2012 to YTD 2018 17

AbbVie Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 18

AbbVie Inc, Pharmaceuticals & Healthcare, Deal Details 27

Asset Purchase 27

AbbVie Acquires Rights of BI-655066 and BI-655064 from Boehringer Ingelheim 27

AbbVie Acquires Active Pharmaceutical Ingredient Manufacturing Facility 28

AbbVie Acquires Rights to Ribasphere from Kadmon 29

Venture Financing 30

Morphic Therapeutic Raises USD80 Million in Series B Financing 30

ApoGen Biotech Raises Additional USD4 Million in Series A Financing 32

Quentis Therapeutics Raises USD48 Million in Series A Financing 34

Jnana Therapeutics Raises USD50 Million in Series A Financing 36

Palleon Pharma Raises USD47.6 Million in Series A Financing 37

Disarm Therapeutics Raises USD30 Million in Series A Financing 38

Rodeo Therapeutics Raises USD5.9 Million in Series A Financing 39

eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 41

CARMA Therapeutics Raises Fund through Venture Financing 43

ApoGen Biotech Raises USD7 Million in Series A Financing 44

Artios Pharma Raises USD33.2 Million in Series A Financing 46

Morphic Therapeutic Raises USD51.5 Million in Series A Venture Financing 48

Lodo Therapeutics Raises USD17 Million in Series A Financing 50

Alector Raises USD29.5 Million in Series D Financing 52

Petra Pharma Raises USD48 Million in Series A Financing 54

Effector Therapeutics Raises USD40 Million in Series B Venture Financing 56

Stemcentrx Raises USD500 Million in Financing Round 58

Stemcentrx Raises USD250 Million in Financing Round 59

Stem CentRx Raises more than USD100 Million in Financing Round 60

AM-Pharma Raised USD15.8 Million in Series E Venture Financing 61

Virobay Raises USD8 Million in Extended Series B Financing 63

Kala Pharma Raises USD 22.5 Million In Series B Venture Financing 65

AuraSense Therapeutics Raises Funds Through Extended Series B Financing 67

Avaxia Biologics Raises USD 11.4 Million In Series B Financing 68

Alvine Pharmaceuticals Secures USD70 Million in Venture Funding from AbbVie Biotech Ventures 70

Partnerships 71

AbbVie and Morphic Therapeutic to Enter into Agreement 71

Tolero Pharma Enters into Research Agreement with AbbVie 72

IRICoR, University of Montreal Enter into Research Agreement with AbbVie 73

Oncternal Therapeutics Enters into Agreement with Pharmacyclics 75

Voyager Therapeutics Enters into Agreement with AbbVie Biotechnology 76

AbbVie Enters into Agreement with Alector 78

AbbVie and Harpoon Therapeutics Enter into Research Partnership 79

AbbVie and Turnstone Biologics Enter into Research Agreement 80

AbbVie and Bristol-Myers Squibb Enter into Agreement 81

AbbVie and Principia Biopharma Enter into Agreement 82

Argen-X Enters Into Agreement with AbbVie 83

Zebra Biologics Enters into Agreement with AbbVie 84

AbbVie Enters into Agreement with Genomics Medicine Ireland and WuXi NextCODE Genomics 85

AbbVie Enters into Research Agreement with Robert H. Lurie Comprehensive Cancer Center of Northwestern University 86

AbbVie Enters into Research Agreement with Johns Hopkins University School of Medicine 87

AbbVie Enters into Agreement with BioArctic 88

X-Chem Enters into Co-Development Agreement with AbbVie 89

AbbVie and Bristol-Myers Squibb Enter into Agreement 90

EA Pharma Enters into Co-Promotion Agreement with AbbVie 91

AbbVie Enters into Research Agreement with University of Chicago 92

Myriad Genetics Expands Research Agreement with AbbVie for Veliparib 93

Philogen Enters into R&D Agreement with AbbVie 94

Synlogic Enters into R&D Agreement with AbbVie 95

AbbVie Enters into Co-Development Agreement with University of Texas MD Anderson Cancer Center 96

AbbVie Deutschland Enters into Partnership Agreement with Eisai 97

Enterome Enters into Co-Development Agreement with AbbVie 98

Calico Expands Co-Development Agreement with AbbVie 99

Seattle Genetics Expands Co-Development Agreement With AbbVie 100

Myriad Genetics Expands Research Agreement with AbbVie 101

AbbVie Expands its Agreement with Galapagos 102

AbbVie Enters Into Co-Development Agreement With Alvine Pharma For ALV003 104

Inventiva Extends Agreement with AbbVie 105

Licensing Agreements 106

AbbVie Enters into Licensing Agreement with Momenta Pharma 106

AbbVie Exercises Option for Licensing Agreement with Argenx 107

Mylan Enters into Licensing Agreement with AbbVie 108

AbbVie to Enter into Licensing Agreement with California Institute for Biomedical Research 109

E-Scape Enters into Licensing Agreement with AbbVie 110

Samsung Bioepis Enters into Licensing Agreement with AbbVie 111

AbbVie Exercises Option for Licensing Agreement with X-Chem 112

AbbVie Exercises Option for Licensing Agreement with Philogen 113

AbbVie Enters into Licensing Agreement with Pure MHC 114

AbbVie Enters into Licensing Agreement with Dong-A ST 115

AbbVie Enters into Licensing Agreement with CytomX Therapeutics 116

AbbVie Enters into Licensing Agreement with CytomX Therapeutics for CD71 118

Halozyme Therapeutics Enters into Licensing Agreement with AbbVie 120

AbbVie Enters into License Agreement with C2N Diagnostics for Alzheimer's Disease Therapy 121

AbbVie Enters into Licensing Agreement with Apogenix 122

Medicines Patent Pool Enters into Licensing Agreement with AbbVie 123

AbbVie Enters into Licensing Agreement with Kadmon for Ribasphere 124

Pharmacyclics Amends Licensing Agreement With Novo Nordisk For PCI-27483 125

AbbVie Enters into Licensing Agreement with Life Science Pharma and Seattle Genetics 126

F-star Bio Enters into Licensing agreement with AbbVie 127

Medicines Patent Pool Enters into Licensing Agreement with AbbVie 128

Receptos Enters Into Licensing Agreement With AbbVie For RPC4046 129

Equity Offering 130

Exicure Raises USD20 Million in Private Placement 130

Aquinnah Pharma Raises USD10 Million in Private Placement of Shares 131

Pharmacyclics Completes Public Offering Of Shares For USD 207 Million 132

AbbVie Spin Out from Abbott Laboratories 133

AbbVie Completes IPO 134

Debt Offering 135

AbbVie Raises USD1.25 Billion in Public Offering of 3.375% Notes Due 2021 135

AbbVie Raises USD1.25 Billion in Public Offering of 3.75% Notes Due 2023 137

AbbVie Raises USD1.75 Billion in Public Offering of 4.25% Notes Due 2028 139

AbbVie Raises USD1.75 Billion in Public Offering of 4.875% Notes Due 2048 141

AbbVie Raises USD795.6 Million in Public Offering of 2.13% Notes Due 2028 143

AbbVie Raises USD1.53 Billion in Public Offering of 1.38% Notes Due 2024 144

AbbVie Raises USD1.48 Billion in Public Offering of 0.38% Notes Due 2019 145

AbbVie to Raise USD1.8 Billion in Public Offering of 2.3% Notes Due 2021 146

AbbVie to Raise USD2 Billion in Public Offering of 4.45% Notes Due 2046 148

AbbVie to Raise USD1 Billion in Public Offering of 2.85% Notes Due 2023 150

AbbVie to Raise USD2 Billion in Public Offering of 3.2% Notes Due 2026 152

AbbVie to Raise USD1 Billion in Public Offering of 4.3% Notes Due 2036 154

AbbVie Raises USD3 Billion in Public Offering of 1.8% Notes Due 2018 156

AbbVie Raises USD3.75 Billion in Public Offering of 3.6% Notes Due 2025 158

AbbVie Raises USD2.5 Billion in Public Offering of 4.5% Notes Due 2035 160

AbbVie Raises USD3.75 Billion in Public Offering of 2.5% Notes Due 2020 162

AbbVie Raises USD1 Billion in Public Offering of 3.2% Notes Due 2022 164

AbbVie Raises USD2.7 Billion in Public Offering of 4.7% Notes Due 2045 166

AbbVie Raises USD1 Billion in Public Offering of 2% Notes Due 2018 168

AbbVie Raises USD2.6 Billion in Public Offering of 4.4% Notes Due 2042 169

AbbVie Raises USD3.1 Billion in Public Offering of 2.9% Notes Due 2022 170

AbbVie Raises USD4 Billion in Public Offering of 1.75% Notes Due 2017 171

Acquisition 172

AbbVie Acquires Stemcentrx 172

AbbVie Acquires Pharmacyclics 173

AbbVie Acquires ImmuVen from Serra Ventures 175

AbbVie Inc - Key Competitors 176

AbbVie Inc - Key Employees 177

AbbVie Inc - Locations And Subsidiaries 178

Head Office 178

Other Locations & Subsidiaries 178

Recent Developments 187

Strategy And Business Planning 187

Jan 16, 2018: AbbVie Expands Oncology Capability at the Company's Site in Ballytivnan, Sligo 187

Financial Announcements 188

Sep 30, 2018: Abbvie reports third-quarter 2018 financial results 188

Jul 27, 2018: AbbVie Reports Second-Quarter 2018 Financial Results 190

Apr 26, 2018: AbbVie Reports First-Quarter 2018 Financial Results 193

Jan 26, 2018: AbbVie Reports Full-Year and Fourth-Quarter 2017 Financial Results 195

Oct 27, 2017: AbbVie Reports Third-Quarter 2017 Financial Results 197

Jul 28, 2017: AbbVie Reports Second-Quarter 2017 Financial Results 199

Apr 27, 2017: AbbVie Reports First-Quarter 2017 Financial Results 201

Jan 27, 2017: AbbVie Reports Full-Year and Fourth-Quarter 2016 Financial Results 203

Corporate Communications 205

Oct 19, 2018: AbbVie announces senior management change 205

Sep 21, 2018: AbbVie announces $5 Million donation to family reach to support children battling cancer and their families 206

Aug 20, 2018: AbbVie announces 100 million donation to Ronald McDonald House Charities to support hospitalized children and their families 207

May 22, 2018: AbbVie Donates $100 Million to Strengthen Access to Healthcare, Housing for Hurricane-Ravaged Puerto Rico 208

Jul 31, 2017: AbbVie Announces Delisting from Euronext Paris 210

Legal and Regulatory 211

Mar 28, 2018: AbbVie pays $5m to man who claims testosterone drug caused heart attack 211

Government and Public Interest 212

Oct 24, 2018: AbbVie to assume full development and commercial control of Cystic Fibrosis research program 212

Oct 15, 2018: Rival companies to tap $20bn global market with biosimilars for Humira 213

Dec 05, 2017: Bioethics International Releases the "Good Pharma Scorecard" in BMJ Open, Ranking the Top 20 Largest Pharmaceutical Companies on Clinical Trial Transparency 214

Mar 28, 2017: AbbVie and M2Gen Announce New Collaboration for the Oncology Research Information Exchange Network (ORIEN) Avatar Research Program 215

Product News 216

12/14/2017: LSTMs AWOL Consortium Celebrates 10-year Milestone 216

11/21/2017: AbbVie to Present Data on Cancer Drug Candidate ABBV-621 at the 2017 American Society of Hematology Annual Meeting & Exposition 217

11/01/2017: Data To Be Presented On Venclexta At ASH 2017 Annual Meeting 218

10/30/2017: Janssen Announces IMBRUVICA (ibrutinib) as the First Approved Treatment for Chronic Graft-Versus-Host Disease (cGVHD) Granted by Health Canada Priority Review 219

10/25/2017: Nail psoriasis data now part of HUMIRA label 221

10/24/2017: New hope of a treatment for aggressive T-PLL leukaemia 222

10/24/2017: AbbVie to Present New Data on HUMIRA at the 2017 ACR/ARHP Annual Meeting 223

09/25/2018: AbbVie receives approval from health canada for the combination of VENCLEXTA with Rituximab as a treatment for patients with chronic lymphocytic leukemia 225

08/30/2017: China Food and Drug Administration approves IMBRUVICA (ibrutinib) for the treatment of two forms of blood cancer with high unmet treatment needs 226

08/29/2017: More Canadians have access to HUMIRA (adalimumab) for the treatment of Ulcerative Colitis 227

08/02/2017: U.S. FDA Approves IMBRUVICA (ibrutinib) as First Approved Treatment Specifically for Adults with Chronic Graft-Versus-Host-Disease (cGVHD) - A Serious, Potentially Life-Threatening Condition - After Failure of One or More Lines of Systemic Therapy 228

07/28/2017: FDA grants breakthrough therapy designation for Venclexta in acute myeloid leukaemia 230

07/21/2017: AbbVie Receives CHMP Positive Opinion for HUMIRA (adalimumab) for the Treatment of Pediatric Patients with Chronic Non-infectious Anterior Uveitis 231

06/28/2018: argenx receives second preclinical milestone payment under its development agreement with AbbVie 233

06/21/2018: AbbVie and Eisai Announce the Launch of HUMIRA for Subcutaneous Injection 20 mg Syringe 0.2 mL, A New Pediatric Formulation of HUMIRA 234

06/13/2017: AbbVie Presents Real-World Data Evaluating the Relationship between Participation in a Patient Support Program and Outcomes in Patients with Moderate to Severe Rheumatoid Arthritis 235

06/11/2018: AbbVie and Eisai Announce the Launch of HUMIRA Pen, an Auto-Injector Formulation for Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA 237

06/08/2018: AbbVie Announces U.S. FDA Approval of VENCLEXTA (venetoclax tablets) in Combination with Rituximab as a Fixed Duration Treatment for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Patients Who Have Received One Prior Therapy 238

06/05/2017: New Data Presented at ASCO 2017 Finds IMBRUVICA (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia Treatment than Chemotherapy Agent Chlorambucil in Treatment-Naive Patients 241

05/22/2017: New cancer drug can prevent reactions to common airborne allergens 243

05/16/2018: AbbVie to Show Progress and Growth in Oncology Research at the American Society of Clinical Oncology 2018 Annual Meeting 244

04/13/2018: Two Clinical Trials Demonstrate Effectiveness Of Venetoclax 245

04/13/2017: argenx receives first preclinical milestone payment in AbbVie collaboration 246

04/11/2017: Scottish Medicines Consortium recommends Imbruvica (ibrutinib) for restricted use in patients with Chronic Lymphocytic Leukaemia in Scotland 247

04/05/2018: Chemo Free Cancer Treatment Thanks To Victorian Research 248

03/30/2017: U.S. FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie's HUMIRA (adalimumab) Prescribing Information 249

03/23/2018: AbbVie and Eisai Obtain Additional Approval for New Indication of Fully Human Anti-TNF-a Monoclonal Antibody HUMIRA in the Treatment of Patients who have had an Inadequate Response to Conventional Therapy for Pustular Psoriasis 250

03/06/2018: AbbVie Receives Positive Recommendation from the Pan-Canadian Oncology Drug Review for VENCLEXTA - an Oral Therapy for the Treatment of Patients with Chronic Lymphocytic Leukemia 251

02/21/2018: Canadians living with Moderate to Severe Hidradenitis Suppurativa are beginning to have public access to HUMIRA (Adalimumab) to manage their disease 252

01/26/2017: National Institute for Health and Care Excellence (NICE) approves Imbruvica (ibrutinib) for routine NHS use in patients with chronic lymphocytic leukaemia 253

01/19/2017: U.S. FDA Approves IMBRUVICA (ibrutinib) as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma (MZL) - a Rare Type of Non-Hodgkin's Lymphoma 254

Product Approvals 256

Jul 12, 2018: AbbVie submits venetoclax sNDA for acute myeloid leukaemia 256

Jan 15, 2018: AbbVie's Humira Rejects For Use Within NHS Scotland 257

Nov 13, 2017: Janssen-Cilag's Imbruvica Rejects For Use Within NHS Scotland 258

Sep 28, 2017: NICE U-turn on Imbruvica(ibrutinib) means patients with Waldenstrom's macroglobulinaemia can now access the only licensed novel agent available for this rare blood cancer 259

Aug 07, 2017: Scotland first in the UK to make VENCLYXTO (venetoclax) routinely available for patients with most common form of leukaemia 260

Jun 12, 2017: AbbVie's Humira accepted for use in NHS Scotland 262

Jun 12, 2017: Janssen-Cilag's Imbruvica Rejects For Use Within NHS Scotland 263

Apr 25, 2017: AbbVie Files Application for Humira in Japan for Additional Indication of Pustular Psoriasis 264

Apr 04, 2017: U.S. FDA Accepts for Review the Application of Ibrutinib (IMBRUVICA) for Chronic Graft-Versus-Host-Disease (cGVHD) After Failure of One or More Lines of Systemic Therapy 265

Jan 10, 2017: Australian Approval For Drug That Melts' Leukaemia 266

Clinical Trials 267

Oct 24, 2018: Galapagos announces topline interim results of FALCON trial Part 1 with in CF 267

Oct 24, 2018: Galapagos announces topline interim results of FALCON trial Part 1 in cystic fibrosis 268

Sep 11, 2018: Minimal residual disease negativity data, a measure of undetectable disease, added to VENCLEXTA (venetoclax tablets) label 269

Jun 28, 2018: Topline results of PELICAN trial and update on triple combo development plans 271

Jun 15, 2018: AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress 272

May 31, 2018: AbbVie to Present New Data from Several Investigational Studies of Venetoclax as Monotherapy or in Combination for the Management of a Number of Difficult-to-Treat Blood Cancers at 23rd European Hematology Association (EHA) Annual Congress 274

Apr 24, 2018: Galapagos reports initiation of FALCON clinical trial in cystic fibrosis 276

Feb 12, 2018: AbbVie to Present Data on HUMIRA at 2018 American Academy of Dermatology Annual Meeting 277

Jan 03, 2018: Galapagos: Update on Progress in GLPG2222 Cystic Fibrosis Program 278

Jan 02, 2018: Galapagos Announces First dosing in Phase 1 study with second triple combination 279

Jan 02, 2018: Galapagos Announces Start of Phase 1 study with GLPG2851, $10 million milestone payment 280

Jan 02, 2018: Galapagos Expects first dosing of CF patient with investigational triple combination therapy 281

Dec 12, 2017: AbbVie Announces Phase 3 Study of VENCLEXTA/ VENCLYXTO (venetoclax) in Combination with Rituxan (rituximab) Meets its Primary Endpoint 282

Nov 21, 2017: AbbVie to Present Data on Ibrutinib at the 2017 American Society of Hematology Annual Meeting & Exposition 284

Nov 21, 2017: Galapagos initiates Phase 1 study with novel CF corrector GLPG3221 286

Nov 21, 2017: Phase 3 MURANO Study of Venetoclax Chosen as Late-Breaking Abstract at the 2017 American Society of Hematology Annual Meeting & Exposition 287

Nov 19, 2017: ALBATROSS with GLPG2222 shows positive clinical results in CF patients 289

Nov 01, 2017: Janssen to Present Abstracts on IMBRUVICA (ibrutinib) at ASH 2017 290

Oct 05, 2017: NICE recommends access to AbbVie's VENCLYXTO (venetoclax) to treat most common form of adult leukaemia in England via Cancer Drugs Fund 292

Sep 18, 2017: Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan 294

Jun 24, 2017: European Hematology Association: Multicenter Open-label Phase 2 Study of ibrutinib in Chronic Graft Versus Host Disease (cGVHD) After Failure of Corticosteroids 295

Jun 23, 2017: Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers 296

Jun 19, 2017: Three-Year Follow-Up Data Showed Patients Achieved Four-Fold Progression-Free Survival Benefit with Single Agent Imbruvica (ibrutinib) vs Temsirolimus at First Relapse in Mantle Cell Lymphoma 298

Jun 12, 2017: AbbVie Announces New Data Evaluating Venetoclax in a Variety of Hematologic Malignancies at the 22nd European Hematology Association Congress 300

Jun 05, 2017: Data at ASCO Show Consistent Progression-Free Survival Benefit in Relapsed/Refractory Chronic Lymphocytic Leukaemia Patients Treated with Imbruvica (ibrutinib), Including Those with High-Risk Disease, with Up to Four Years of Follow-Up 302

Jun 05, 2017: Long-Term IMBRUVICA (ibrutinib) Efficacy and Safety Data at ASCO 2017 Show Sustained Survival Rates in Up to Four Years in Previously-Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Patients, Including Those with High-Risk Disease 304

May 17, 2017: Janssen to Present Data on Ibrutinib at the American Society of Clinical Oncology 306

May 14, 2017: IMBRUVICA (ibrutinib) Pooled Outcomes Data from Three Phase 3 Studies Suggest Potential Clinical Efficacy in Patients with High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 307

Apr 19, 2017: AbbVie Announces Topline Results from Two Phase 3 Studies Investigating Veliparib in Combination with Chemotherapy for the Treatment of Patients with Advanced or Metastatic Squamous Non-Small Cell Lung Cancer and Early-Stage Triple-Negative Breast Cancer 309

Apr 11, 2017: Apogenix Announces Initiation of Clinical Development for ABBV-621 to Treat Solid and Hematologic Tumors by Partner AbbVie 310

Mar 22, 2017: Galapagos initiates Phase 1 study with novel CF potentiator GLPG3067 311

Feb 24, 2017: Evaluating A Novel Chemo-free Combination Therapy for Lymphocytic Leukemia 312

Feb 23, 2017: Galapagos doses first healthy volunteer with CF combo GLPG2222 and GLPG2451 313

Feb 01, 2017: Galapagos doses first patient with novel CF corrector GLPG2222 314

Appendix 315

Methodology 315

About GlobalData 315

Contact Us 315

Disclaimer 315


List Of Figure

List of Figures

AbbVie Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 12

AbbVie Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 13

AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 14

AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 15

AbbVie Inc, Medical Devices Deals, 2012 to YTD 2018 17


List Of Table

List of Tables

AbbVie Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 12

AbbVie Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 13

AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 14

AbbVie Inc, Deals By Therapy Area, 2012 to YTD 2018 15

AbbVie Inc, Medical Devices Deals, 2012 to YTD 2018 17

AbbVie Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 18

AbbVie Acquires Rights of BI-655066 and BI-655064 from Boehringer Ingelheim 27

AbbVie Acquires Active Pharmaceutical Ingredient Manufacturing Facility 28

AbbVie Acquires Rights to Ribasphere from Kadmon 29

Morphic Therapeutic Raises USD80 Million in Series B Financing 30

ApoGen Biotech Raises Additional USD4 Million in Series A Financing 32

Quentis Therapeutics Raises USD48 Million in Series A Financing 34

Jnana Therapeutics Raises USD50 Million in Series A Financing 36

Palleon Pharma Raises USD47.6 Million in Series A Financing 37

Disarm Therapeutics Raises USD30 Million in Series A Financing 38

Rodeo Therapeutics Raises USD5.9 Million in Series A Financing 39

eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 41

CARMA Therapeutics Raises Fund through Venture Financing 43

ApoGen Biotech Raises USD7 Million in Series A Financing 44

Artios Pharma Raises USD33.2 Million in Series A Financing 46

Morphic Therapeutic Raises USD51.5 Million in Series A Venture Financing 48

Lodo Therapeutics Raises USD17 Million in Series A Financing 50

Alector Raises USD29.5 Million in Series D Financing 52

Petra Pharma Raises USD48 Million in Series A Financing 54

Effector Therapeutics Raises USD40 Million in Series B Venture Financing 56

Stemcentrx Raises USD500 Million in Financing Round 58

Stemcentrx Raises USD250 Million in Financing Round 59

Stem CentRx Raises more than USD100 Million in Financing Round 60

AM-Pharma Raised USD15.8 Million in Series E Venture Financing 61

Virobay Raises USD8 Million in Extended Series B Financing 63

Kala Pharma Raises USD 22.5 Million In Series B Venture Financing 65

AuraSense Therapeutics Raises Funds Through Extended Series B Financing 67

Avaxia Biologics Raises USD 11.4 Million In Series B Financing 68

Alvine Pharmaceuticals Secures USD70 Million in Venture Funding from AbbVie Biotech Ventures 70

AbbVie and Morphic Therapeutic to Enter into Agreement 71

Tolero Pharma Enters into Research Agreement with AbbVie 72

IRICoR, University of Montreal Enter into Research Agreement with AbbVie 73

Oncternal Therapeutics Enters into Agreement with Pharmacyclics 75

Voyager Therapeutics Enters into Agreement with AbbVie Biotechnology 76

AbbVie Enters into Agreement with Alector 78

AbbVie and Harpoon Therapeutics Enter into Research Partnership 79

AbbVie and Turnstone Biologics Enter into Research Agreement 80

AbbVie and Bristol-Myers Squibb Enter into Agreement 81

AbbVie and Principia Biopharma Enter into Agreement 82

Argen-X Enters Into Agreement with AbbVie 83

Zebra Biologics Enters into Agreement with AbbVie 84

AbbVie Enters into Agreement with Genomics Medicine Ireland and WuXi NextCODE Genomics 85

AbbVie Enters into Research Agreement with Robert H. Lurie Comprehensive Cancer Center of Northwestern University 86

AbbVie Enters into Research Agreement with Johns Hopkins University School of Medicine 87

AbbVie Enters into Agreement with BioArctic 88

X-Chem Enters into Co-Development Agreement with AbbVie 89

AbbVie and Bristol-Myers Squibb Enter into Agreement 90

EA Pharma Enters into Co-Promotion Agreement with AbbVie 91

AbbVie Enters into Research Agreement with University of Chicago 92

Myriad Genetics Expands Research Agreement with AbbVie for Veliparib 93

Philogen Enters into R&D Agreement with AbbVie 94

Synlogic Enters into R&D Agreement with AbbVie 95

AbbVie Enters into Co-Development Agreement with University of Texas MD Anderson Cancer Center 96

AbbVie Deutschland Enters into Partnership Agreement with Eisai 97

Enterome Enters into Co-Development Agreement with AbbVie 98

Calico Expands Co-Development Agreement with AbbVie 99

Seattle Genetics Expands Co-Development Agreement With AbbVie 100

Myriad Genetics Expands Research Agreement with AbbVie 101

AbbVie Expands its Agreement with Galapagos 102

AbbVie Enters Into Co-Development Agreement With Alvine Pharma For ALV003 104

Inventiva Extends Agreement with AbbVie 105

AbbVie Enters into Licensing Agreement with Momenta Pharma 106

AbbVie Exercises Option for Licensing Agreement with Argenx 107

Mylan Enters into Licensing Agreement with AbbVie 108

AbbVie to Enter into Licensing Agreement with California Institute for Biomedical Research 109

E-Scape Enters into Licensing Agreement with AbbVie 110

Samsung Bioepis Enters into Licensing Agreement with AbbVie 111

AbbVie Exercises Option for Licensing Agreement with X-Chem 112

AbbVie Exercises Option for Licensing Agreement with Philogen 113

AbbVie Enters into Licensing Agreement with Pure MHC 114

AbbVie Enters into Licensing Agreement with Dong-A ST 115

AbbVie Enters into Licensing Agreement with CytomX Therapeutics 116

AbbVie Enters into Licensing Agreement with CytomX Therapeutics for CD71 118

Halozyme Therapeutics Enters into Licensing Agreement with AbbVie 120

AbbVie Enters into License Agreement with C2N Diagnostics for Alzheimer's Disease Therapy 121

AbbVie Enters into Licensing Agreement with Apogenix 122

Medicines Patent Pool Enters into Licensing Agreement with AbbVie 123

AbbVie Enters into Licensing Agreement with Kadmon for Ribasphere 124

Pharmacyclics Amends Licensing Agreement With Novo Nordisk For PCI-27483 125

AbbVie Enters into Licensing Agreement with Life Science Pharma and Seattle Genetics 126

F-star Bio Enters into Licensing agreement with AbbVie 127

Medicines Patent Pool Enters into Licensing Agreement with AbbVie 128

Receptos Enters Into Licensing Agreement With AbbVie For RPC4046 129

Exicure Raises USD20 Million in Private Placement 130

Aquinnah Pharma Raises USD10 Million in Private Placement of Shares 131

Pharmacyclics Completes Public Offering Of Shares For USD 207 Million 132

AbbVie Spin Out from Abbott Laboratories 133

AbbVie Completes IPO 134

AbbVie Raises USD1.25 Billion in Public Offering of 3.375% Notes Due 2021 135

AbbVie Raises USD1.25 Billion in Public Offering of 3.75% Notes Due 2023 137

AbbVie Raises USD1.75 Billion in Public Offering of 4.25% Notes Due 2028 139

AbbVie Raises USD1.75 Billion in Public Offering of 4.875% Notes Due 2048 141

AbbVie Raises USD795.6 Million in Public Offering of 2.13% Notes Due 2028 143

AbbVie Raises USD1.53 Billion in Public Offering of 1.38% Notes Due 2024 144

AbbVie Raises USD1.48 Billion in Public Offering of 0.38% Notes Due 2019 145

AbbVie to Raise USD1.8 Billion in Public Offering of 2.3% Notes Due 2021 146

AbbVie to Raise USD2 Billion in Public Offering of 4.45% Notes Due 2046 148

AbbVie to Raise USD1 Billion in Public Offering of 2.85% Notes Due 2023 150

AbbVie to Raise USD2 Billion in Public Offering of 3.2% Notes Due 2026 152

AbbVie to Raise USD1 Billion in Public Offering of 4.3% Notes Due 2036 154

AbbVie Raises USD3 Billion in Public Offering of 1.8% Notes Due 2018 156

AbbVie Raises USD3.75 Billion in Public Offering of 3.6% Notes Due 2025 158

AbbVie Raises USD2.5 Billion in Public Offering of 4.5% Notes Due 2035 160

AbbVie Raises USD3.75 Billion in Public Offering of 2.5% Notes Due 2020 162

AbbVie Raises USD1 Billion in Public Offering of 3.2% Notes Due 2022 164

AbbVie Raises USD2.7 Billion in Public Offering of 4.7% Notes Due 2045 166

AbbVie Raises USD1 Billion in Public Offering of 2% Notes Due 2018 168

AbbVie Raises USD2.6 Billion in Public Offering of 4.4% Notes Due 2042 169

AbbVie Raises USD3.1 Billion in Public Offering of 2.9% Notes Due 2022 170

AbbVie Raises USD4 Billion in Public Offering of 1.75% Notes Due 2017 171

AbbVie Acquires Stemcentrx 172

AbbVie Acquires Pharmacyclics 173

AbbVie Acquires ImmuVen from Serra Ventures 175

AbbVie Inc, Key Competitors 176

AbbVie Inc, Key Employees 177

AbbVie Inc, Subsidiaries 178

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

AbbVie Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company that develops, manufactures and commercializes advanced therapies for treating complex and serious diseases. It provides pharmaceutical drugs to treat conditions in rheumatology, gastroenterology, dermatology, oncology, virology and metabolic therapy areas. The company also offers medicines for neurological disorders and other serious health conditions. AbbVie discovers and develops novel medicines based on protein-based and targeted drug delivery technologies. The company its products directly to wholesalers, distributors, health care facilities, government agencies, specialty pharmacies and independent retailers through its own distribution centers and public warehouses across the world. AbbVie is headquartered in North Chicago, Illinois, the US.

AbbVie Inc (ABBV)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 9

List of Figures 11

AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 12

AbbVie Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 13

AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 14

AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 15

AbbVie Inc, Medical Devices Deals, 2012 to YTD 2018 17

AbbVie Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 18

AbbVie Inc, Pharmaceuticals & Healthcare, Deal Details 27

Asset Purchase 27

AbbVie Acquires Rights of BI-655066 and BI-655064 from Boehringer Ingelheim 27

AbbVie Acquires Active Pharmaceutical Ingredient Manufacturing Facility 28

AbbVie Acquires Rights to Ribasphere from Kadmon 29

Venture Financing 30

Morphic Therapeutic Raises USD80 Million in Series B Financing 30

ApoGen Biotech Raises Additional USD4 Million in Series A Financing 32

Quentis Therapeutics Raises USD48 Million in Series A Financing 34

Jnana Therapeutics Raises USD50 Million in Series A Financing 36

Palleon Pharma Raises USD47.6 Million in Series A Financing 37

Disarm Therapeutics Raises USD30 Million in Series A Financing 38

Rodeo Therapeutics Raises USD5.9 Million in Series A Financing 39

eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 41

CARMA Therapeutics Raises Fund through Venture Financing 43

ApoGen Biotech Raises USD7 Million in Series A Financing 44

Artios Pharma Raises USD33.2 Million in Series A Financing 46

Morphic Therapeutic Raises USD51.5 Million in Series A Venture Financing 48

Lodo Therapeutics Raises USD17 Million in Series A Financing 50

Alector Raises USD29.5 Million in Series D Financing 52

Petra Pharma Raises USD48 Million in Series A Financing 54

Effector Therapeutics Raises USD40 Million in Series B Venture Financing 56

Stemcentrx Raises USD500 Million in Financing Round 58

Stemcentrx Raises USD250 Million in Financing Round 59

Stem CentRx Raises more than USD100 Million in Financing Round 60

AM-Pharma Raised USD15.8 Million in Series E Venture Financing 61

Virobay Raises USD8 Million in Extended Series B Financing 63

Kala Pharma Raises USD 22.5 Million In Series B Venture Financing 65

AuraSense Therapeutics Raises Funds Through Extended Series B Financing 67

Avaxia Biologics Raises USD 11.4 Million In Series B Financing 68

Alvine Pharmaceuticals Secures USD70 Million in Venture Funding from AbbVie Biotech Ventures 70

Partnerships 71

AbbVie and Morphic Therapeutic to Enter into Agreement 71

Tolero Pharma Enters into Research Agreement with AbbVie 72

IRICoR, University of Montreal Enter into Research Agreement with AbbVie 73

Oncternal Therapeutics Enters into Agreement with Pharmacyclics 75

Voyager Therapeutics Enters into Agreement with AbbVie Biotechnology 76

AbbVie Enters into Agreement with Alector 78

AbbVie and Harpoon Therapeutics Enter into Research Partnership 79

AbbVie and Turnstone Biologics Enter into Research Agreement 80

AbbVie and Bristol-Myers Squibb Enter into Agreement 81

AbbVie and Principia Biopharma Enter into Agreement 82

Argen-X Enters Into Agreement with AbbVie 83

Zebra Biologics Enters into Agreement with AbbVie 84

AbbVie Enters into Agreement with Genomics Medicine Ireland and WuXi NextCODE Genomics 85

AbbVie Enters into Research Agreement with Robert H. Lurie Comprehensive Cancer Center of Northwestern University 86

AbbVie Enters into Research Agreement with Johns Hopkins University School of Medicine 87

AbbVie Enters into Agreement with BioArctic 88

X-Chem Enters into Co-Development Agreement with AbbVie 89

AbbVie and Bristol-Myers Squibb Enter into Agreement 90

EA Pharma Enters into Co-Promotion Agreement with AbbVie 91

AbbVie Enters into Research Agreement with University of Chicago 92

Myriad Genetics Expands Research Agreement with AbbVie for Veliparib 93

Philogen Enters into R&D Agreement with AbbVie 94

Synlogic Enters into R&D Agreement with AbbVie 95

AbbVie Enters into Co-Development Agreement with University of Texas MD Anderson Cancer Center 96

AbbVie Deutschland Enters into Partnership Agreement with Eisai 97

Enterome Enters into Co-Development Agreement with AbbVie 98

Calico Expands Co-Development Agreement with AbbVie 99

Seattle Genetics Expands Co-Development Agreement With AbbVie 100

Myriad Genetics Expands Research Agreement with AbbVie 101

AbbVie Expands its Agreement with Galapagos 102

AbbVie Enters Into Co-Development Agreement With Alvine Pharma For ALV003 104

Inventiva Extends Agreement with AbbVie 105

Licensing Agreements 106

AbbVie Enters into Licensing Agreement with Momenta Pharma 106

AbbVie Exercises Option for Licensing Agreement with Argenx 107

Mylan Enters into Licensing Agreement with AbbVie 108

AbbVie to Enter into Licensing Agreement with California Institute for Biomedical Research 109

E-Scape Enters into Licensing Agreement with AbbVie 110

Samsung Bioepis Enters into Licensing Agreement with AbbVie 111

AbbVie Exercises Option for Licensing Agreement with X-Chem 112

AbbVie Exercises Option for Licensing Agreement with Philogen 113

AbbVie Enters into Licensing Agreement with Pure MHC 114

AbbVie Enters into Licensing Agreement with Dong-A ST 115

AbbVie Enters into Licensing Agreement with CytomX Therapeutics 116

AbbVie Enters into Licensing Agreement with CytomX Therapeutics for CD71 118

Halozyme Therapeutics Enters into Licensing Agreement with AbbVie 120

AbbVie Enters into License Agreement with C2N Diagnostics for Alzheimer's Disease Therapy 121

AbbVie Enters into Licensing Agreement with Apogenix 122

Medicines Patent Pool Enters into Licensing Agreement with AbbVie 123

AbbVie Enters into Licensing Agreement with Kadmon for Ribasphere 124

Pharmacyclics Amends Licensing Agreement With Novo Nordisk For PCI-27483 125

AbbVie Enters into Licensing Agreement with Life Science Pharma and Seattle Genetics 126

F-star Bio Enters into Licensing agreement with AbbVie 127

Medicines Patent Pool Enters into Licensing Agreement with AbbVie 128

Receptos Enters Into Licensing Agreement With AbbVie For RPC4046 129

Equity Offering 130

Exicure Raises USD20 Million in Private Placement 130

Aquinnah Pharma Raises USD10 Million in Private Placement of Shares 131

Pharmacyclics Completes Public Offering Of Shares For USD 207 Million 132

AbbVie Spin Out from Abbott Laboratories 133

AbbVie Completes IPO 134

Debt Offering 135

AbbVie Raises USD1.25 Billion in Public Offering of 3.375% Notes Due 2021 135

AbbVie Raises USD1.25 Billion in Public Offering of 3.75% Notes Due 2023 137

AbbVie Raises USD1.75 Billion in Public Offering of 4.25% Notes Due 2028 139

AbbVie Raises USD1.75 Billion in Public Offering of 4.875% Notes Due 2048 141

AbbVie Raises USD795.6 Million in Public Offering of 2.13% Notes Due 2028 143

AbbVie Raises USD1.53 Billion in Public Offering of 1.38% Notes Due 2024 144

AbbVie Raises USD1.48 Billion in Public Offering of 0.38% Notes Due 2019 145

AbbVie to Raise USD1.8 Billion in Public Offering of 2.3% Notes Due 2021 146

AbbVie to Raise USD2 Billion in Public Offering of 4.45% Notes Due 2046 148

AbbVie to Raise USD1 Billion in Public Offering of 2.85% Notes Due 2023 150

AbbVie to Raise USD2 Billion in Public Offering of 3.2% Notes Due 2026 152

AbbVie to Raise USD1 Billion in Public Offering of 4.3% Notes Due 2036 154

AbbVie Raises USD3 Billion in Public Offering of 1.8% Notes Due 2018 156

AbbVie Raises USD3.75 Billion in Public Offering of 3.6% Notes Due 2025 158

AbbVie Raises USD2.5 Billion in Public Offering of 4.5% Notes Due 2035 160

AbbVie Raises USD3.75 Billion in Public Offering of 2.5% Notes Due 2020 162

AbbVie Raises USD1 Billion in Public Offering of 3.2% Notes Due 2022 164

AbbVie Raises USD2.7 Billion in Public Offering of 4.7% Notes Due 2045 166

AbbVie Raises USD1 Billion in Public Offering of 2% Notes Due 2018 168

AbbVie Raises USD2.6 Billion in Public Offering of 4.4% Notes Due 2042 169

AbbVie Raises USD3.1 Billion in Public Offering of 2.9% Notes Due 2022 170

AbbVie Raises USD4 Billion in Public Offering of 1.75% Notes Due 2017 171

Acquisition 172

AbbVie Acquires Stemcentrx 172

AbbVie Acquires Pharmacyclics 173

AbbVie Acquires ImmuVen from Serra Ventures 175

AbbVie Inc - Key Competitors 176

AbbVie Inc - Key Employees 177

AbbVie Inc - Locations And Subsidiaries 178

Head Office 178

Other Locations & Subsidiaries 178

Recent Developments 187

Strategy And Business Planning 187

Jan 16, 2018: AbbVie Expands Oncology Capability at the Company's Site in Ballytivnan, Sligo 187

Financial Announcements 188

Sep 30, 2018: Abbvie reports third-quarter 2018 financial results 188

Jul 27, 2018: AbbVie Reports Second-Quarter 2018 Financial Results 190

Apr 26, 2018: AbbVie Reports First-Quarter 2018 Financial Results 193

Jan 26, 2018: AbbVie Reports Full-Year and Fourth-Quarter 2017 Financial Results 195

Oct 27, 2017: AbbVie Reports Third-Quarter 2017 Financial Results 197

Jul 28, 2017: AbbVie Reports Second-Quarter 2017 Financial Results 199

Apr 27, 2017: AbbVie Reports First-Quarter 2017 Financial Results 201

Jan 27, 2017: AbbVie Reports Full-Year and Fourth-Quarter 2016 Financial Results 203

Corporate Communications 205

Oct 19, 2018: AbbVie announces senior management change 205

Sep 21, 2018: AbbVie announces $5 Million donation to family reach to support children battling cancer and their families 206

Aug 20, 2018: AbbVie announces 100 million donation to Ronald McDonald House Charities to support hospitalized children and their families 207

May 22, 2018: AbbVie Donates $100 Million to Strengthen Access to Healthcare, Housing for Hurricane-Ravaged Puerto Rico 208

Jul 31, 2017: AbbVie Announces Delisting from Euronext Paris 210

Legal and Regulatory 211

Mar 28, 2018: AbbVie pays $5m to man who claims testosterone drug caused heart attack 211

Government and Public Interest 212

Oct 24, 2018: AbbVie to assume full development and commercial control of Cystic Fibrosis research program 212

Oct 15, 2018: Rival companies to tap $20bn global market with biosimilars for Humira 213

Dec 05, 2017: Bioethics International Releases the "Good Pharma Scorecard" in BMJ Open, Ranking the Top 20 Largest Pharmaceutical Companies on Clinical Trial Transparency 214

Mar 28, 2017: AbbVie and M2Gen Announce New Collaboration for the Oncology Research Information Exchange Network (ORIEN) Avatar Research Program 215

Product News 216

12/14/2017: LSTMs AWOL Consortium Celebrates 10-year Milestone 216

11/21/2017: AbbVie to Present Data on Cancer Drug Candidate ABBV-621 at the 2017 American Society of Hematology Annual Meeting & Exposition 217

11/01/2017: Data To Be Presented On Venclexta At ASH 2017 Annual Meeting 218

10/30/2017: Janssen Announces IMBRUVICA (ibrutinib) as the First Approved Treatment for Chronic Graft-Versus-Host Disease (cGVHD) Granted by Health Canada Priority Review 219

10/25/2017: Nail psoriasis data now part of HUMIRA label 221

10/24/2017: New hope of a treatment for aggressive T-PLL leukaemia 222

10/24/2017: AbbVie to Present New Data on HUMIRA at the 2017 ACR/ARHP Annual Meeting 223

09/25/2018: AbbVie receives approval from health canada for the combination of VENCLEXTA with Rituximab as a treatment for patients with chronic lymphocytic leukemia 225

08/30/2017: China Food and Drug Administration approves IMBRUVICA (ibrutinib) for the treatment of two forms of blood cancer with high unmet treatment needs 226

08/29/2017: More Canadians have access to HUMIRA (adalimumab) for the treatment of Ulcerative Colitis 227

08/02/2017: U.S. FDA Approves IMBRUVICA (ibrutinib) as First Approved Treatment Specifically for Adults with Chronic Graft-Versus-Host-Disease (cGVHD) - A Serious, Potentially Life-Threatening Condition - After Failure of One or More Lines of Systemic Therapy 228

07/28/2017: FDA grants breakthrough therapy designation for Venclexta in acute myeloid leukaemia 230

07/21/2017: AbbVie Receives CHMP Positive Opinion for HUMIRA (adalimumab) for the Treatment of Pediatric Patients with Chronic Non-infectious Anterior Uveitis 231

06/28/2018: argenx receives second preclinical milestone payment under its development agreement with AbbVie 233

06/21/2018: AbbVie and Eisai Announce the Launch of HUMIRA for Subcutaneous Injection 20 mg Syringe 0.2 mL, A New Pediatric Formulation of HUMIRA 234

06/13/2017: AbbVie Presents Real-World Data Evaluating the Relationship between Participation in a Patient Support Program and Outcomes in Patients with Moderate to Severe Rheumatoid Arthritis 235

06/11/2018: AbbVie and Eisai Announce the Launch of HUMIRA Pen, an Auto-Injector Formulation for Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA 237

06/08/2018: AbbVie Announces U.S. FDA Approval of VENCLEXTA (venetoclax tablets) in Combination with Rituximab as a Fixed Duration Treatment for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Patients Who Have Received One Prior Therapy 238

06/05/2017: New Data Presented at ASCO 2017 Finds IMBRUVICA (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia Treatment than Chemotherapy Agent Chlorambucil in Treatment-Naive Patients 241

05/22/2017: New cancer drug can prevent reactions to common airborne allergens 243

05/16/2018: AbbVie to Show Progress and Growth in Oncology Research at the American Society of Clinical Oncology 2018 Annual Meeting 244

04/13/2018: Two Clinical Trials Demonstrate Effectiveness Of Venetoclax 245

04/13/2017: argenx receives first preclinical milestone payment in AbbVie collaboration 246

04/11/2017: Scottish Medicines Consortium recommends Imbruvica (ibrutinib) for restricted use in patients with Chronic Lymphocytic Leukaemia in Scotland 247

04/05/2018: Chemo Free Cancer Treatment Thanks To Victorian Research 248

03/30/2017: U.S. FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie's HUMIRA (adalimumab) Prescribing Information 249

03/23/2018: AbbVie and Eisai Obtain Additional Approval for New Indication of Fully Human Anti-TNF-a Monoclonal Antibody HUMIRA in the Treatment of Patients who have had an Inadequate Response to Conventional Therapy for Pustular Psoriasis 250

03/06/2018: AbbVie Receives Positive Recommendation from the Pan-Canadian Oncology Drug Review for VENCLEXTA - an Oral Therapy for the Treatment of Patients with Chronic Lymphocytic Leukemia 251

02/21/2018: Canadians living with Moderate to Severe Hidradenitis Suppurativa are beginning to have public access to HUMIRA (Adalimumab) to manage their disease 252

01/26/2017: National Institute for Health and Care Excellence (NICE) approves Imbruvica (ibrutinib) for routine NHS use in patients with chronic lymphocytic leukaemia 253

01/19/2017: U.S. FDA Approves IMBRUVICA (ibrutinib) as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma (MZL) - a Rare Type of Non-Hodgkin's Lymphoma 254

Product Approvals 256

Jul 12, 2018: AbbVie submits venetoclax sNDA for acute myeloid leukaemia 256

Jan 15, 2018: AbbVie's Humira Rejects For Use Within NHS Scotland 257

Nov 13, 2017: Janssen-Cilag's Imbruvica Rejects For Use Within NHS Scotland 258

Sep 28, 2017: NICE U-turn on Imbruvica(ibrutinib) means patients with Waldenstrom's macroglobulinaemia can now access the only licensed novel agent available for this rare blood cancer 259

Aug 07, 2017: Scotland first in the UK to make VENCLYXTO (venetoclax) routinely available for patients with most common form of leukaemia 260

Jun 12, 2017: AbbVie's Humira accepted for use in NHS Scotland 262

Jun 12, 2017: Janssen-Cilag's Imbruvica Rejects For Use Within NHS Scotland 263

Apr 25, 2017: AbbVie Files Application for Humira in Japan for Additional Indication of Pustular Psoriasis 264

Apr 04, 2017: U.S. FDA Accepts for Review the Application of Ibrutinib (IMBRUVICA) for Chronic Graft-Versus-Host-Disease (cGVHD) After Failure of One or More Lines of Systemic Therapy 265

Jan 10, 2017: Australian Approval For Drug That Melts' Leukaemia 266

Clinical Trials 267

Oct 24, 2018: Galapagos announces topline interim results of FALCON trial Part 1 with in CF 267

Oct 24, 2018: Galapagos announces topline interim results of FALCON trial Part 1 in cystic fibrosis 268

Sep 11, 2018: Minimal residual disease negativity data, a measure of undetectable disease, added to VENCLEXTA (venetoclax tablets) label 269

Jun 28, 2018: Topline results of PELICAN trial and update on triple combo development plans 271

Jun 15, 2018: AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress 272

May 31, 2018: AbbVie to Present New Data from Several Investigational Studies of Venetoclax as Monotherapy or in Combination for the Management of a Number of Difficult-to-Treat Blood Cancers at 23rd European Hematology Association (EHA) Annual Congress 274

Apr 24, 2018: Galapagos reports initiation of FALCON clinical trial in cystic fibrosis 276

Feb 12, 2018: AbbVie to Present Data on HUMIRA at 2018 American Academy of Dermatology Annual Meeting 277

Jan 03, 2018: Galapagos: Update on Progress in GLPG2222 Cystic Fibrosis Program 278

Jan 02, 2018: Galapagos Announces First dosing in Phase 1 study with second triple combination 279

Jan 02, 2018: Galapagos Announces Start of Phase 1 study with GLPG2851, $10 million milestone payment 280

Jan 02, 2018: Galapagos Expects first dosing of CF patient with investigational triple combination therapy 281

Dec 12, 2017: AbbVie Announces Phase 3 Study of VENCLEXTA/ VENCLYXTO (venetoclax) in Combination with Rituxan (rituximab) Meets its Primary Endpoint 282

Nov 21, 2017: AbbVie to Present Data on Ibrutinib at the 2017 American Society of Hematology Annual Meeting & Exposition 284

Nov 21, 2017: Galapagos initiates Phase 1 study with novel CF corrector GLPG3221 286

Nov 21, 2017: Phase 3 MURANO Study of Venetoclax Chosen as Late-Breaking Abstract at the 2017 American Society of Hematology Annual Meeting & Exposition 287

Nov 19, 2017: ALBATROSS with GLPG2222 shows positive clinical results in CF patients 289

Nov 01, 2017: Janssen to Present Abstracts on IMBRUVICA (ibrutinib) at ASH 2017 290

Oct 05, 2017: NICE recommends access to AbbVie's VENCLYXTO (venetoclax) to treat most common form of adult leukaemia in England via Cancer Drugs Fund 292

Sep 18, 2017: Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan 294

Jun 24, 2017: European Hematology Association: Multicenter Open-label Phase 2 Study of ibrutinib in Chronic Graft Versus Host Disease (cGVHD) After Failure of Corticosteroids 295

Jun 23, 2017: Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers 296

Jun 19, 2017: Three-Year Follow-Up Data Showed Patients Achieved Four-Fold Progression-Free Survival Benefit with Single Agent Imbruvica (ibrutinib) vs Temsirolimus at First Relapse in Mantle Cell Lymphoma 298

Jun 12, 2017: AbbVie Announces New Data Evaluating Venetoclax in a Variety of Hematologic Malignancies at the 22nd European Hematology Association Congress 300

Jun 05, 2017: Data at ASCO Show Consistent Progression-Free Survival Benefit in Relapsed/Refractory Chronic Lymphocytic Leukaemia Patients Treated with Imbruvica (ibrutinib), Including Those with High-Risk Disease, with Up to Four Years of Follow-Up 302

Jun 05, 2017: Long-Term IMBRUVICA (ibrutinib) Efficacy and Safety Data at ASCO 2017 Show Sustained Survival Rates in Up to Four Years in Previously-Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Patients, Including Those with High-Risk Disease 304

May 17, 2017: Janssen to Present Data on Ibrutinib at the American Society of Clinical Oncology 306

May 14, 2017: IMBRUVICA (ibrutinib) Pooled Outcomes Data from Three Phase 3 Studies Suggest Potential Clinical Efficacy in Patients with High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 307

Apr 19, 2017: AbbVie Announces Topline Results from Two Phase 3 Studies Investigating Veliparib in Combination with Chemotherapy for the Treatment of Patients with Advanced or Metastatic Squamous Non-Small Cell Lung Cancer and Early-Stage Triple-Negative Breast Cancer 309

Apr 11, 2017: Apogenix Announces Initiation of Clinical Development for ABBV-621 to Treat Solid and Hematologic Tumors by Partner AbbVie 310

Mar 22, 2017: Galapagos initiates Phase 1 study with novel CF potentiator GLPG3067 311

Feb 24, 2017: Evaluating A Novel Chemo-free Combination Therapy for Lymphocytic Leukemia 312

Feb 23, 2017: Galapagos doses first healthy volunteer with CF combo GLPG2222 and GLPG2451 313

Feb 01, 2017: Galapagos doses first patient with novel CF corrector GLPG2222 314

Appendix 315

Methodology 315

About GlobalData 315

Contact Us 315

Disclaimer 315


List Of Figure

List of Figures

AbbVie Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 12

AbbVie Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 13

AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 14

AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 15

AbbVie Inc, Medical Devices Deals, 2012 to YTD 2018 17


List Of Table

List of Tables

AbbVie Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 12

AbbVie Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 13

AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 14

AbbVie Inc, Deals By Therapy Area, 2012 to YTD 2018 15

AbbVie Inc, Medical Devices Deals, 2012 to YTD 2018 17

AbbVie Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 18

AbbVie Acquires Rights of BI-655066 and BI-655064 from Boehringer Ingelheim 27

AbbVie Acquires Active Pharmaceutical Ingredient Manufacturing Facility 28

AbbVie Acquires Rights to Ribasphere from Kadmon 29

Morphic Therapeutic Raises USD80 Million in Series B Financing 30

ApoGen Biotech Raises Additional USD4 Million in Series A Financing 32

Quentis Therapeutics Raises USD48 Million in Series A Financing 34

Jnana Therapeutics Raises USD50 Million in Series A Financing 36

Palleon Pharma Raises USD47.6 Million in Series A Financing 37

Disarm Therapeutics Raises USD30 Million in Series A Financing 38

Rodeo Therapeutics Raises USD5.9 Million in Series A Financing 39

eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 41

CARMA Therapeutics Raises Fund through Venture Financing 43

ApoGen Biotech Raises USD7 Million in Series A Financing 44

Artios Pharma Raises USD33.2 Million in Series A Financing 46

Morphic Therapeutic Raises USD51.5 Million in Series A Venture Financing 48

Lodo Therapeutics Raises USD17 Million in Series A Financing 50

Alector Raises USD29.5 Million in Series D Financing 52

Petra Pharma Raises USD48 Million in Series A Financing 54

Effector Therapeutics Raises USD40 Million in Series B Venture Financing 56

Stemcentrx Raises USD500 Million in Financing Round 58

Stemcentrx Raises USD250 Million in Financing Round 59

Stem CentRx Raises more than USD100 Million in Financing Round 60

AM-Pharma Raised USD15.8 Million in Series E Venture Financing 61

Virobay Raises USD8 Million in Extended Series B Financing 63

Kala Pharma Raises USD 22.5 Million In Series B Venture Financing 65

AuraSense Therapeutics Raises Funds Through Extended Series B Financing 67

Avaxia Biologics Raises USD 11.4 Million In Series B Financing 68

Alvine Pharmaceuticals Secures USD70 Million in Venture Funding from AbbVie Biotech Ventures 70

AbbVie and Morphic Therapeutic to Enter into Agreement 71

Tolero Pharma Enters into Research Agreement with AbbVie 72

IRICoR, University of Montreal Enter into Research Agreement with AbbVie 73

Oncternal Therapeutics Enters into Agreement with Pharmacyclics 75

Voyager Therapeutics Enters into Agreement with AbbVie Biotechnology 76

AbbVie Enters into Agreement with Alector 78

AbbVie and Harpoon Therapeutics Enter into Research Partnership 79

AbbVie and Turnstone Biologics Enter into Research Agreement 80

AbbVie and Bristol-Myers Squibb Enter into Agreement 81

AbbVie and Principia Biopharma Enter into Agreement 82

Argen-X Enters Into Agreement with AbbVie 83

Zebra Biologics Enters into Agreement with AbbVie 84

AbbVie Enters into Agreement with Genomics Medicine Ireland and WuXi NextCODE Genomics 85

AbbVie Enters into Research Agreement with Robert H. Lurie Comprehensive Cancer Center of Northwestern University 86

AbbVie Enters into Research Agreement with Johns Hopkins University School of Medicine 87

AbbVie Enters into Agreement with BioArctic 88

X-Chem Enters into Co-Development Agreement with AbbVie 89

AbbVie and Bristol-Myers Squibb Enter into Agreement 90

EA Pharma Enters into Co-Promotion Agreement with AbbVie 91

AbbVie Enters into Research Agreement with University of Chicago 92

Myriad Genetics Expands Research Agreement with AbbVie for Veliparib 93

Philogen Enters into R&D Agreement with AbbVie 94

Synlogic Enters into R&D Agreement with AbbVie 95

AbbVie Enters into Co-Development Agreement with University of Texas MD Anderson Cancer Center 96

AbbVie Deutschland Enters into Partnership Agreement with Eisai 97

Enterome Enters into Co-Development Agreement with AbbVie 98

Calico Expands Co-Development Agreement with AbbVie 99

Seattle Genetics Expands Co-Development Agreement With AbbVie 100

Myriad Genetics Expands Research Agreement with AbbVie 101

AbbVie Expands its Agreement with Galapagos 102

AbbVie Enters Into Co-Development Agreement With Alvine Pharma For ALV003 104

Inventiva Extends Agreement with AbbVie 105

AbbVie Enters into Licensing Agreement with Momenta Pharma 106

AbbVie Exercises Option for Licensing Agreement with Argenx 107

Mylan Enters into Licensing Agreement with AbbVie 108

AbbVie to Enter into Licensing Agreement with California Institute for Biomedical Research 109

E-Scape Enters into Licensing Agreement with AbbVie 110

Samsung Bioepis Enters into Licensing Agreement with AbbVie 111

AbbVie Exercises Option for Licensing Agreement with X-Chem 112

AbbVie Exercises Option for Licensing Agreement with Philogen 113

AbbVie Enters into Licensing Agreement with Pure MHC 114

AbbVie Enters into Licensing Agreement with Dong-A ST 115

AbbVie Enters into Licensing Agreement with CytomX Therapeutics 116

AbbVie Enters into Licensing Agreement with CytomX Therapeutics for CD71 118

Halozyme Therapeutics Enters into Licensing Agreement with AbbVie 120

AbbVie Enters into License Agreement with C2N Diagnostics for Alzheimer's Disease Therapy 121

AbbVie Enters into Licensing Agreement with Apogenix 122

Medicines Patent Pool Enters into Licensing Agreement with AbbVie 123

AbbVie Enters into Licensing Agreement with Kadmon for Ribasphere 124

Pharmacyclics Amends Licensing Agreement With Novo Nordisk For PCI-27483 125

AbbVie Enters into Licensing Agreement with Life Science Pharma and Seattle Genetics 126

F-star Bio Enters into Licensing agreement with AbbVie 127

Medicines Patent Pool Enters into Licensing Agreement with AbbVie 128

Receptos Enters Into Licensing Agreement With AbbVie For RPC4046 129

Exicure Raises USD20 Million in Private Placement 130

Aquinnah Pharma Raises USD10 Million in Private Placement of Shares 131

Pharmacyclics Completes Public Offering Of Shares For USD 207 Million 132

AbbVie Spin Out from Abbott Laboratories 133

AbbVie Completes IPO 134

AbbVie Raises USD1.25 Billion in Public Offering of 3.375% Notes Due 2021 135

AbbVie Raises USD1.25 Billion in Public Offering of 3.75% Notes Due 2023 137

AbbVie Raises USD1.75 Billion in Public Offering of 4.25% Notes Due 2028 139

AbbVie Raises USD1.75 Billion in Public Offering of 4.875% Notes Due 2048 141

AbbVie Raises USD795.6 Million in Public Offering of 2.13% Notes Due 2028 143

AbbVie Raises USD1.53 Billion in Public Offering of 1.38% Notes Due 2024 144

AbbVie Raises USD1.48 Billion in Public Offering of 0.38% Notes Due 2019 145

AbbVie to Raise USD1.8 Billion in Public Offering of 2.3% Notes Due 2021 146

AbbVie to Raise USD2 Billion in Public Offering of 4.45% Notes Due 2046 148

AbbVie to Raise USD1 Billion in Public Offering of 2.85% Notes Due 2023 150

AbbVie to Raise USD2 Billion in Public Offering of 3.2% Notes Due 2026 152

AbbVie to Raise USD1 Billion in Public Offering of 4.3% Notes Due 2036 154

AbbVie Raises USD3 Billion in Public Offering of 1.8% Notes Due 2018 156

AbbVie Raises USD3.75 Billion in Public Offering of 3.6% Notes Due 2025 158

AbbVie Raises USD2.5 Billion in Public Offering of 4.5% Notes Due 2035 160

AbbVie Raises USD3.75 Billion in Public Offering of 2.5% Notes Due 2020 162

AbbVie Raises USD1 Billion in Public Offering of 3.2% Notes Due 2022 164

AbbVie Raises USD2.7 Billion in Public Offering of 4.7% Notes Due 2045 166

AbbVie Raises USD1 Billion in Public Offering of 2% Notes Due 2018 168

AbbVie Raises USD2.6 Billion in Public Offering of 4.4% Notes Due 2042 169

AbbVie Raises USD3.1 Billion in Public Offering of 2.9% Notes Due 2022 170

AbbVie Raises USD4 Billion in Public Offering of 1.75% Notes Due 2017 171

AbbVie Acquires Stemcentrx 172

AbbVie Acquires Pharmacyclics 173

AbbVie Acquires ImmuVen from Serra Ventures 175

AbbVie Inc, Key Competitors 176

AbbVie Inc, Key Employees 177

AbbVie Inc, Subsidiaries 178

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

AbbVie Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.